Ligand Pharmaceuticals Announces License Agreement With bluebird bio, Inc.

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in connection with its worldwide OmniAb Platform License Agreement with bluebird bio, Inc. (NASDAQ: BLUE) for antibody development. Under the agreement, Ligand is eligible to receive annual platform access payments, development milestone payments and royalties for each product that incorporates an OmniAb antibody.

Ligand is a biopharmaceutical company that focuses on developing and or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. bluebird bio is a clinical stage company that develops potentially transformative gene therapies for severe genetic disease and T cell-based immunotherapies.

San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.